HCW Biologics granted extension by Nasdaq to regain listing compliance

HCW Biologics (HCWB) reported that the Nasdaq Hearings Panel granted the company an extension in which to regain compliance with all continued listing rules of Nasdaq. The Panel’s determination follows a hearing on February 13 at which the Panel considered the company’s plan to regain compliance with the minimum bid price, the market value of publicly held securities and the market value of listed securities rules, respectively. As a result of the extension, the Panel granted the Company’s request for continued listing on the Exchange, provided that the company demonstrates compliance with the Bid Price Rule by April 25 and all other Exchange continued listing rules by June 15.